Lung Cancer News

CHICAGO — Retrospective data showed how common central nervous system metastases are among patients with non-small cell lung cancer and ALK or ROS1 alterations who have been treated with tyrosine kinase inhibitors.

CHICAGO — Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial.

CHICAGO — Analysis of the SEER database showed a significant decline of rates of advanced lung cancer following screening guidelines for low-dose chest computed tomography.

Erik Knudsen, PhD, has been appointed associate director of basic science research at Roswell Park Comprehensive Cancer Center.

Active systemic cancer treatment did not appear associated with increased mortality among patients with cancer and COVID-19, according to study results published in JAMA Network Open.

In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ASCO Annual Meeting.

In this video, Jia Luo, MD, spoke with Healio about an educational session she chaired at ASCO Annual Meeting.

Men, older patients and patients with low income were among those with elevated risk for CVD hospitalization prior to receiving a diagnosis of potentially curable cancer, researchers reported.

In this video, Melina Marmarelis, MD, discussed results from two FDA pooled analyses in lung cancer that were presented at the ASCO annual meeting.

CHICAGO – For patients with extensive-stage small cell lung cancer, a first-line treatment of serplulimab plus chemotherapy provided significant benefit and safety profile compared with chemotherapy alone.